Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cystadenocarcinoma, Serous × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 59 Breast Neoplasms 18 Prostatic Neoplasms 14 Neoplasms 14 Fallopian Tube Neoplasms 13 Neoplasm Metastasis 8 Pancreatic Neoplasms 7 Glioblastoma 7 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Melanoma 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Mesothelioma, Malignant 2 Mesothelioma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

ribociclib 1 niraparib 1 Specimen Handling 1 Paclitaxel 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Letrozole 1 Ipilimumab 1 Diphenhydramine 1 Dexamethasone 1 Cimetidine 1 CTLA-4 Antigen 1 Blood Specimen Collection 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04159155 2025-08-12

CAN-STAMP

University Health Network, Toronto

Phase 2/3 Terminated

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡